相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
Ralph A. DeFronzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Edward S. Horton et al.
DIABETES CARE (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
IMPROVED GLYCEMIC CONTROL WITH INSULIN GLARGINE VERSUS PIOGLITAZONE AS ADD-ON THERAPY TO SULFONYLUREA OR METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
Luigi F. Meneghini et al.
ENDOCRINE PRACTICE (2010)
Regulatory Action on Rosiglitazone by the US Food and Drug Administration
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Revisiting the Rosiglitazone Story - Lessons Learned
Clifford J. Rosen
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lipoprotein lipase: from gene to obesity
Hong Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Julio Rosenstock et al.
DIABETES CARE (2009)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
S. S. Lund et al.
DIABETES OBESITY & METABOLISM (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus
Takahiro Araki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Philip J. Barter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor
Z. Huang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme
Chamukuttan Snehalatha et al.
DIABETES & VASCULAR DISEASE RESEARCH (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Barriers to medication adherence in poorly controlled diabetes mellitus
Peggy Soule Odegard et al.
DIABETES EDUCATOR (2008)
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
Soren S. Lund et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Is glycemic control improving in US adults?
Thomas J. Hoerger et al.
DIABETES CARE (2008)
The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
Ioanna Eleftheriadou et al.
CURRENT DIABETES REVIEWS (2008)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes
L. Raymond Reynolds et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group
Andrea Mosca et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2007)
Recommendation for term and measurement unit for HbA1c
Gunnar Nordin et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study
H. C. Gerstein et al.
DIABETIC MEDICINE (2006)
Insulin glargine or NPH combined with metformin in type 2 diabetes:: the LANMET study
H Yki-Järvinen et al.
DIABETOLOGIA (2006)
Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
J Rosenstock et al.
DIABETES CARE (2006)
Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002 - The National Health and Nutrition Examination Survey
HE Resnick et al.
DIABETES CARE (2006)
Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes
Y Mori et al.
ENDOCRINE (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators
SH Han et al.
HYPERTENSION (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
VL Roberts et al.
CLINICAL THERAPEUTICS (2005)
Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes
JPH Van Wijk et al.
DIABETES CARE (2005)
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial
G Derosa et al.
CLINICAL THERAPEUTICS (2004)
Transcriptional control of apolipoprotein A-I gene expression in diabetes
AD Mooradian et al.
DIABETES (2004)
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes
JB Buse et al.
DIABETES OBESITY & METABOLISM (2004)
Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, Randomized trial
K Aljabri et al.
AMERICAN JOURNAL OF MEDICINE (2004)
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus:: a systematic review
MG Wulffelé et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients
M Alvarsson et al.
DIABETES CARE (2003)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
The effect of pneumonia on mortality among patients hospitalized for acute stroke
IL Katzan et al.
NEUROLOGY (2003)
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
H Duez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study
GE Dailey et al.
CLINICAL THERAPEUTICS (2002)
Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes
N Musi et al.
DIABETES (2002)
Metabolic and additional vascular effects of thiazolidinediones
FMAC Martens et al.
DRUGS (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control
CE Tan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2001)
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes
S Salman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2001)
Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients
AA Rivellese et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes:: a stable isotope kinetic study
L Duvillard et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
